| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787274 | Gaceta Mexicana de Oncología | 2016 | 6 Pages |
Abstract
Chemotherapy-induced neutropenia is a frequent and serious complication of the oncological treatment. One of its consequences is the interruption of the cytotoxic treatment, which affects the patient response and quality of life, as well as increasing the cost of medical care. Management of chemotherapy-induced neutropenia must include preventive and therapeutic strategies, which the oncologist must take into account when considering the potential myelosuppressive agent and to implement the appropriate treatment approaches. Granulocyte colony stimulating factors are the cornerstone for the management of this complication and have become quite effective treatment tools.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Pedro de Jesús Sobrevilla Calvo, Nora Sobrevilla Moreno, Francisco Javier Ochoa Carrillo,